ESTRO 2024 - Abstract Book

S1752

Clinical - Lung

ESTRO 2024

median TETT was 8.2 months (95 % CI 5.6-13.6), see Figure 2. At 12 months, the rate of maintaining the same TKI treatment was 36.7 % (95 % CI 25.8-52.3). Reasons for cessation of TKI treatment were progression (52/55, 94 %), adverse events (2 %), poor performance status without radiological progression (2 %), and admittance to the hospital (2 %).

Figure 2. Time from first local therapy until cessation of TKI treatment regimen. A patient can be included more than once in the analysis.

Conclusion:

We found that a local therapy strategy may extend the TKI treatment after limited progression by eight months for patients with ALK or EGFR mutated NSCLC. Core limitations are the retrospective nature of the study, a limited number of patients, as well as our population having “limited progression”, and not “oligoprogression”, reducing the generalizability. Nevertheless, it still shows a potential clinical benefit for select patients. Results from randomized studies such as the CURB [8] and HALT [9] trials are eagerly awaited.

Keywords: Local therapy, progression, TKI

References:

1. Shimamura, S.S., et al., Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients? BMC Cancer, 2022. 22(1): p. 323.

2. Alanazi, A., et al., Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. Lung Cancer Manag, 2020. 10(1): p. Lmt43.